Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer Immunotherapies
Aduro公司扩大与强生创投公司和詹森公司在肺癌免疫疗法上的合作，
Aduro BioTech has entered into its second agreement with Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform. Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro will receive a $30 million up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817 million. In addition, Aduro is eligible to receive high single-digit to double-digit tiered royalties on worldwide net sales upon successful launch and commercialization.
Audro生物科技公司与詹森强生公司的子公司，詹森生物科技公司订立了第二份合作协议，授予后者排他性的、世界范围内的许可，基于其创新的LADD免疫治疗平台，来生产设计用来治疗肺癌和其他癌症的候选产品。根据协议，在位于加利福尼亚州的强生创新中心的协助下，Aduro公司将获得3000万美元的预先付款，并且能够获得数额巨大的研发、调整和商业化阶段的付款，总额预计可达到8.17亿美元。另外，Aduro有资格在药品成功发行和商业化或，获得全世界净销售额一位数或两位数的封层办税提成。
Under the agreement, Janssen will have exclusive rights to develop and commercialize LADD product candidates in lung cancer and will assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. Aduro may provide assistance in any of these areas upon request and will receive additional fees for these support activities.
根据该协议，詹森公司将拥有排他性的权利来研发和商业化治疗肺癌的LADD候选产品，并为授权产品所有的研究、发展、生产、标准和商业化承担责任。Aduro公司可应请求在所有这些方面提供支持，并因这些帮助活动而获得额外报酬。
"Since our initial agreement with Janssen in May of this year for new immunotherapies for prostate cancer, they have been terrific partners and we've established a strong collaboration focused on advancing our technologies forward in their licensed indications," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "We believe our LADD technology also offers tremendous promise as a potential treatment for lung cancer and we are pleased to expand our relationship with Janssen, a company with significant experience and resources focused in both lung and prostate cancer. Separately, Aduro continues to make progress with our broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma among others."
自从我们在今年五月与詹森公司就新的前列腺癌免疫疗法签订首个协议以来，他们是极好的合作伙伴，我们已经建立了强有力的合作，专注于在他们的许可适应症里推广我们的技术。Aduro公司的董事长、总裁和首席执行官Stephen T. Isaacs说。“我相信我们的LADD技术对于治疗肺癌提供了巨大的希望，并且我们很乐意与詹森公司扩大合作，该公司专注肺癌和前列腺癌治疗，拥有丰富的经验和资源。Aduro将继续单独地在许多其他癌症适应症中发展我们广泛的免疫疗法平台，包括胰腺癌、间皮瘤和其他恶性胶质瘤。
The transaction is subject to clearance by the US antitrust authorities under the Hart-Scott-Rodino Act and will become final as soon as such clearance has occurred.
该交易还需要美国反垄断局根据《斯科特•罗迪诺反垄断改进法案》做出正式许可，并且一经许可，即刻生效。
In May of this year, Aduro announced its first agreement with Janssen Biotech, Inc. granting the company an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. Under that agreement, also facilitated by the Johnson & Johnson Innovation center in California, Aduro is eligible to receive up to $365 million in upfront and development and commercialization milestones.
在今年5月，Aduro公司宣布与詹森生物科技公司达成首个协议，授权该公司基于其创新的LADD免疫治疗平台，专门用于治疗前列腺癌的集中候选产品的排他性的世界范围内的生产许可。根据该协议，并借助位于加利福尼亚州的强生创新中心，Aduro公司能够获得提前支付，以及研发和商业化阶段总额达到3.65亿美元的收入。
评论
打印
